Webinar: In Practice: Beyond the Composition of Matter – AI and the Biosimilar Patent Landscape
A commercial biologic may be protected by patents covering formulations, dosing regimens, methods of treatment, manufacturing and purification processes, delivery systems, and other product attributes. That means for biologics, expiration of the foundational composition-of-matter patent rarely determines when patent protection effectively ends or biosimilar competition can begin. This makes a comprehensive patent landscape. Today, AI is changing the scale…
Free